Ingevity (NGVT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
The Capa HS series is the latest example of NGVT's current innovation push, which is extending the performance boundaries of Caprolactone technology.
Ingevity (NGVT) reported earnings 30 days ago. What's next for the stock?
Ingevity's (NGVT) top line declines in Q2 due to the Performance Chemicals segment's repositioning, which included limiting exposure to specific markets within the Industrial Specialties product line.
Ingevity Corporation (NYSE:NGVT ) Q2 2024 Earnings Conference Call August 1, 2024 11:00 AM ET Company Participants John Nypaver - VP, Treasurer & IR John Fortson - President, CEO & Director Mary Hall - CFO, EVP & Treasurer Conference Call Participants John McNulty - BMO Capital Markets Daniel Rizzo - Jefferies Jonathan Tanwanteng - CJS Securities Mike Sison - Wells Fargo Operator Good morning all and thank you all for attending the Ingevity Second Quarter 2024 Earnings Call and Webcast. My name is Brika, and I will be your moderator today.
Ingevity (NGVT) came out with quarterly earnings of $1.01 per share, missing the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $1.41 per share a year ago.
The addition of a new distribution partner in Europe devoted to Ingevity's (NGVT) Capa biodegradable thermoplastics allows the company to better service its customers in the region.